Abstract | BACKGROUND/AIM: PATIENTS AND METHODS: RESULTS: On multivariate analysis, improved LRC was associated with hemoglobin during radiotherapy ≥12 g/dl (p=0.001). VEGF-negativity showed a trend for better LRC on univariate analysis. On multivariate analysis, better MFS was associated with hemoglobin ≥12 g/dl (p=0.012), better performance status (p=0.009) and lower tumor stage (p=0.032). On multivariate analysis, improved survival was associated with hemoglobin ≥12 g/dl (p<0.001) and better performance status (p=0.005). Trends for improved survival were observed for VEGF-negativity and VEGFR-1-negativity on univariate analysis. CONCLUSION:
VEGF showed a trend towards worse LRC and survival, VEGFR-1 towards worse survival. Outcomes were associated with hemoglobin, performance status and tumor stage.
|
Authors | Ergin Kilic, Steven E Schild, Christoph Thorns, Amira Bajrovic, Dirk Rades |
Journal | Anticancer research
(Anticancer Res)
Vol. 34
Issue 9
Pg. 5221-6
(Sep 2014)
ISSN: 1791-7530 [Electronic] Greece |
PMID | 25202119
(Publication Type: Journal Article)
|
Copyright | Copyright© 2014 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved. |
Chemical References |
- Vascular Endothelial Growth Factor A
- Vascular Endothelial Growth Factor Receptor-1
|
Topics |
- Adult
- Aged
- Esophageal Neoplasms
(metabolism, mortality, pathology, therapy)
- Female
- Follow-Up Studies
- Humans
- Male
- Middle Aged
- Neoplasm Grading
- Neoplasm Staging
- Prognosis
- Treatment Outcome
- Vascular Endothelial Growth Factor A
(metabolism)
- Vascular Endothelial Growth Factor Receptor-1
(metabolism)
|